Boston Scientific Corporation $BSX Shares Bought by Capstone Capital Management Ltd

Capstone Capital Management Ltd lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 576.3% during the 1st quarter, HoldingsChannel.com reports. The fund owned 41,209 shares of the medical equipment provider’s stock after acquiring an additional 35,116 shares during the quarter. Boston Scientific makes up about 2.5% of Capstone Capital Management Ltd’s investment portfolio, making the stock its 10th biggest position. Capstone Capital Management Ltd’s holdings in Boston Scientific were worth $2,586,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. FWL Investment Management LLC bought a new position in Boston Scientific in the 2nd quarter worth approximately $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific during the 4th quarter valued at about $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific during the 4th quarter worth about $26,000. Bangor Savings Bank raised its position in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares in the last quarter. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Boston Scientific in the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, Director David C. Habiger purchased 2,250 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig acquired 3,580 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This represents a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Stock Performance

Shares of BSX opened at $44.77 on Thursday. The firm has a market cap of $66.54 billion, a price-to-earnings ratio of 18.73, a price-to-earnings-growth ratio of 0.87 and a beta of 0.58. The company’s fifty day moving average is $49.93 and its 200-day moving average is $68.22. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 12 month low of $42.25 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. Boston Scientific’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts expect that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its board has initiated a stock buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Wall Street Analyst Weigh In

BSX has been the subject of several recent analyst reports. Wolfe Research cut shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Canaccord Genuity Group cut their target price on Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Raymond James Financial reaffirmed an “outperform” rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Oppenheimer set a $90.00 target price on shares of Boston Scientific in a report on Thursday, April 23rd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Boston Scientific in a report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $81.32.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.